Archive for February, 2011

Studies on the Genome Structure of Neurovirulent and Attenuated Polioviruses – a BLAST from the past

Thursday, February 17th, 2011

colony hybridization In 1979 a young researcher blundered into a laboratory and began working towards a PhD. Four years later, he emergerd blinking into the sunlight and headed off to California for a while. This is the story of those years, which has lain buried under a layer of dust ever since until it was recently published online. Along the way, we had some laughs. For example, this may amuse some people:

Data Handling
Nucleotide sequence data was entered and analysed on a PDP 11/4 computer using a package of programs obtained from R. Staden, MRC Laboratory of Molecular Biology, Cambridge, UK (Staden, 1980).

At any rate, the truth can now be told:

Title: Studies on the Genome Structure of Neurovirulent and Attenuated Polioviruses
Author: Cann, Alan James
Date: 1984
Publisher: University of Leicester
Description: Thesis submitted for the degree of Doctor of Philosophy at the University of Leicester, 1984.
Abstract: The RNA genomes of neurovirulent and attenuated type 3 polioviruses have been cloned in E. coli using an efficient RNA.cDNA hybrid technique. The complete nucleotide sequence of the vaccine-associated neurovirulent revertant P3/119 and, in collaboration with others, the attenuated vaccine strain P3/Leon 12 a1b, have been determined. These have been compared with that of the neurovirulent parent strain P3/Leon/37. Ten nucleotide sequence differences were observed between the parent P3/Leon/37 and the vaccine P3/Leon 12 a1b, three of which resulted in amino acid substitutions. Between the vaccine and the revertant P3/119, seven nucleotide sequence differences were observed. Three of these resulted in amino acid substitutions. The possible significance of individual nucleotide sequence differences to the attenuation of and reversion to neurovirulence in poliovirus type 3 is discussed. The nucleotide sequence of P3/Leon 12 a1b was the first to be determined for a type 3 poliovirus. Comparison of this sequence with published type 1 sequences has demonstrated the extent of the molecular homology between them.

Summary:
The major objective of this study was to identify the nucleotide sequence differences which account for the neurovirulent or attenuated phenotype of three closely related strains of poliovirus type 3. To achieve this, an efficient RNA.cDNA hybrid cloning method was devised. Although this was not the first report of hybrid cloning, previous unfavourable comments on its efficiency (Wood and Lee, 1976; Zain et al., 1979) and suggestions that the method given rise to cloning artefacts (Okayama and Berg, 1982) have almost certainly discouraged widespread use. Thorough investigation of each of the manipulative steps involved has shown that these problems can be overcome (Cann et al, 1983). Comparable in efficiency to the more used double-stranded cDNA cloning technique, the hybrid method has the advantages of experimental simplicity and that cDNA clones corresponding to entire virus genome can be obtained from a single experiment. The method has proved to be ideally suited to the molecular cloning of picornavirus genomes. It is possible that the transformation efficiency of RNA.cDNA hybrids could be further increased by treatment with E. coli DNA ligase and DNA polymerase I before ligation, thus carrying out repair of the hybrid molecule in vitro, as in the method of Okayama and Berg (1982). This modification has not yet been tested.
Together with the work of Dr G. Stanway on the neurovirulent strains P3/Leon/37 and P3/119, hundreds of cDNA clones were examined and more than 22 kbp of nucleotide sequence determined. These experiments resulted in the identification of a mall number of mutations in the genomes of the strains studied which must be responsible for their differences in neurovirulence. However, it has not yet been possible to identify the individual mutations involved in attenuation and reversion and further experiments are currently in progress. These experiments represent a number of different approaches. Firstly, the sequence of other neurovirulent vaccine revertants are being determined, to ascertain whether the mutations observed in P3/119 are shared by other strains. Secondly, the work of Racaniello and Baltimore (1981a) has demonstrated that the construction of recombinant virus genomes in vitro, at the level of cloned cDNA, is possible. Transfection of susceptible cells with these recombinant genomes gives rise to new, viable viruses with a defined set of mutations which can then be examined phenotypically. Initial experiments with recombinants between the neurovirulent strain P3/Leon/37 and the vaccine strain P3/Leon 12 a1b and also between the vaccine strain and the neurovirulent revertant P3/119 are in progress. Final proof that the mutations involved in attenuation and reversion have been accurately identified could be provided by the construction of an attenuated strain by recombination between P3/Leon/37 and P3/119. Parallel studies on neurovirulent and attenuated type 1 strains should help to explain the different stabilities of the type 1 and type 3 vaccines and may suggest how the type 3 vaccine can be modified to improve Stability. Finally, it is hoped to use site-directed mutagenesis of cloned virus genomes ln vitro to produce strains with specific biological properties.
Although the main aim of the work presented here has been the investigation of the molecular basis of attenuation in poliovirus, the information obtained has wider significance. The complete nucleotide sequence of P3/Leon 12 a1b was the first to be determined from a type 3 poliovirus. This has been compares with that of type 1 and the extent of the molecular homology between the demonstrated (Stanway et al, 1983a). As part of a larger study based on the analysis of monoclonal antibody resistant mutants, the major neutralizing antibody binding site of poliovirus type 3 has been identified (Minor et al, 1983). The nucleotide sequence information obtained is also being used currently in the design of synthetic antigenic peptides, a development which may hold many advantages for the prevention and perhaps treatment of poliomyelitis and other related plcornaviral infections. At the outset of the work described in this dissertation, it was difficult to envisage that improved alternativen to the Sabin vaccines would ever be a realistic proposition. It now seems that the immediuate future holds just such a prospect.

Zinc? Don’t make me laugh

Wednesday, February 16th, 2011

zinc The media is buzzing today with the latest incarnation of the “Zinc cures common cold” story. This isn’t new. The first report to show that zinc might be a useful treatment for the common cold was published in 1984. Since then, 18 more trials of zinc for colds have been conducted: 11 of them showed zinc to be a useful treatment, while 7 other trials showed no benefit. The present flap comes about because of a new meta-analysis published in the Cochrane Database of Systematic Reviews.

Sadly, this meta-analysis has got its facts in a twist and obscured the truth. Why? Because there is no evidence that zinc is effective against any viruses other than human rhinoviruses (HRV). And, as I’ve been telling my students for the past few weeks – “the common cold” is not a disease, it’s a symptom, caused by at least five different kinds of virus. Four of which zinc does nothing to. (By the way BBC News, human rinovirus isn’t spread primarily by sneezes, it’s spread by people sticking contaminated fingers up their noses).

So don’t get too excited folks. The next time you get a cold, it won’t be common, you won’t know what virus has infected you and you won’t know whether it’s worth risking the toxic effects of zinc ingestion for a potential “cure” (or not). Nice story, shame about the facts.

Zinc for the common cold (Review). The Cochrane Library 2011, Issue 2

Related:

Those retroviruses get everywhere

Wednesday, February 16th, 2011

Genome Endogenous retroviruses (ERVs) have spread through mammalian genomes throughout evolution, resulting in thousands of copies or fragments of ERVs, encompassing an estimated 7% of the human genome. However, despite their abundance, specific functions could only rarely be assigned to ERVs. The LTRs of such viruses can serve as strong promoters/enhancers, boosting the transcription of viral or adjacent cellular genes. In a recent discovery of a pathologic example in humans, the derepression of an LTR was found to induce the driver proto-oncogene CSF1R in Hodgkin’s lymphoma. The promoter activity of LTRs can display various tissue specificities and is sometimes limited to germ cells. For example, an LTR from the human endogenous retrovirus 9 (ERV9) predominantly transcribes in testis.

Maintaining genomic integrity in the germ line is a fundamental prerequisite for the evolutionary stability of a species. To achieve this, germ cells with damaged DNA need to be efficiently eliminated. This elimination is particularly important when an individual’s fertility is maintained over several decades, as is the case in humans and great apes (Hominidae). In these species, the already long time frame of fertility in females is even more extended in males. However, only very limited knowledge exists on how the genomic integrity of the male germ line is controlled and preserved in humans.

p63 is a homolog of the tumor suppressor p53. In somatic cells, p53 is the quintessential mediator of apoptosis in response to DNA damage, thus acting as the guardian of the genome. Tumor suppressor p53 binds and transcriptionally activates multiple proapoptotic genes. Moreover, p53 directly associates with mitochondria, and by interacting with anti- and proapoptotic members of the Bcl2 family of outer membrane permeability regulators, triggers the release of cytochrome c, jumpstarting apoptosis. This paper shows that unique isoforms of p63 are highly and specifically expressed in human testis as a result of an upstream insertion of an ERV9 LTR with strong promoter activity that occurred 10 to 15 million years ago during primate evolution at the branching point to long-lived Hominidae. Upon DNA damage, the resulting germ cell-associated, transcriptionally active p63 suppresses proliferation and induces apoptosis. Conversely, GTAp63 expression is frequently lost in human testicular cancers.

Endogenous retrovirus drives hitherto unknown proapoptotic p63 isoforms in the male germ line of humans and great apes. PNAS USA February 7 2011. doi: 10.1073/pnas.101620110

Related:

The end of BSE

Tuesday, February 15th, 2011

cow The BSE epidemic cost us billions, and devastated the British farming industry. Now, that plague is at an end. Overall, as many as three million animals were infected; in the peak year, 1992, the UK saw 37,280 diagnoses. Yet there are good reasons why any celebrations have been put on hold. All told, around half a million infected animals entered the food chain. Although it remains unclear how many people ate the most infectious parts, it is clear that the majority of the British population was exposed. So far, the human equivalent of BSE, variant Creutzfeldt-Jakob disease (vCJD), has claimed 170 lives, mainly through consumption of BSE-infected beef. And because of the extraordinary incubation time of the disease, it is possible that many more cases may be waiting in the wings.

Read more: The end of BSE

Engineering microbes to produce biofuels

Tuesday, February 15th, 2011

Biodiesel Chemists and engineers taught us how to wring fuels and chemicals out of rock – the word petroleum derives from Latin roots meaning “rock oil”. In the current world, amid concerns that our sources of petroleum are dwindling, we are turning over all stones for suitable alternatives to petroleum. We need to replace an essentially non-renewable resource, petroleum, with renewable fuels and thus make our future sustainable. The major renewable materials on Earth are derived from biological systems that reproduce and replenish themselves. So it is natural to turn to biological systems for producing renewable fuels. This short review focuses on recent advances in engineering organisms and processes to make renewable fuels.

Engineering microbes to produce biofuels. Curr Opin Biotechnol. Nov 9 2010
The current biofuels landscape is chaotic. It is controlled by the rules imposed by economic forces and driven by the necessity of finding new sources of energy, particularly motor fuels. The need is bringing forth great creativity in uncovering new candidate fuel molecules that can be made via metabolic engineering. These next generation fuels include long-chain alcohols, terpenoid hydrocarbons, and diesel-length alkanes. Renewable fuels contain carbon derived from carbon dioxide. The carbon dioxide is derived directly by a photosynthetic fuel-producing organism(s) or via intermediary biomass polymers that were previously derived from carbon dioxide. To use the latter economically, biomass depolymerization processes must improve and this is a very active area of research. There are competitive approaches with some groups using enzyme based methods and others using chemical catalysts. With the former, feedstock and end-product toxicity loom as major problems. Advances chiefly rest on the ability to manipulate biological systems. Computational and modular construction approaches are key. For example, novel metabolic networks have been constructed to make long-chain alcohols and hydrocarbons that have superior fuel properties over ethanol. A particularly exciting approach is to implement a direct utilization of solar energy to make a usable fuel. A number of approaches use the components of current biological systems, but re-engineer them for more direct, efficient production of fuels.

Related:

Social media: A guide for researchers

Monday, February 14th, 2011

Social media - A guide for researchers While it’s not strictly microbiology, since the purpose of this blog is to promote research through the use of social media, it seems appropriate for me to announce the publication of a new report by the Research Information Network:

Whether or not you’re coming to the Digital Researcher meeting today (in person or participating online), Social media: A guide for researchers is for you. More importantly, since you’re already reading this online, why not download a copy and give it to someone you work with who hasn’t figured out what they’re missing yet.

Disclosure: I am one of the authors :-)

My thanks to everyone who has contributed to this report and helped with publication.

Citation: Cann, A., K. Dimitriou, and T. Hooley. (2011). Social media: A guide for researchers. Research Information Network. http://www.rin.ac.uk/our-work/communicating-and-disseminating-research/social-media-guide-researchers

Smallpox virus: crunch time for the fate of a global killer

Sunday, February 13th, 2011

smallpox “Twenty miles south-east of Novosibirsk, in Siberia, several dozen concrete buildings have been erected outside the town of Koltsovo. The settlement is ringed with triple rows of barbed wire fences. Video cameras and motion sensors monitor any activity near the wires while soldiers from an elite Russian army unit patrol its perimeter.
This is Russia’s State Research Centre of Virology and Biotechnology – or Vector, as it is usually known. Frozen in winter, when temperatures plunge below -30oC, and then scorched in summer, when the heat routinely rises above 30oC, the place is as unwelcoming as you could imagine. Given its name, location and a high-security protection, Vector would make an ideal setting for a James Bond film.
This would be a fitting accolade, for Vector contains a number of unsettling scientific secrets, with the most sinister being housed in bio-containment laboratory P-4, in Building 6. Here a small storage plant, chilled by liquid nitrogen, holds phials of one of the deadliest pathogens known to medical science: the smallpox virus…”

Read more: Smallpox virus: crunch time for the fate of a global killer | The Observer


Meet the newest virus fighter: Salmonella

Saturday, February 12th, 2011

Interfering RNAs (RNAi) are meant to match the sequence of the messenger RNAs made from genes, and then to block or inactivate the mRNA, keeping it from being translated into a harmful protein. One of the main hurdles has been delivering the agents specifically to the cells in which they are needed. An article in this Tuesday’s New York Times drew attention to this problem when reporting that many pharmaceutical companies have suspended their research into RNA interference. But what if you could use a common bacteria to deliver the payload? In work reported in this week’s Proceedings of the National Academies of Sciences, researchers led by Fenyong Liu at UC Berkeley made a modified strain of Salmonella to deliver interfering RNA exactly where it was needed. The result: they inhibited cytomegaloviral infection in mice.

ArsTechnica: Meet the newest virus fighter: Salmonella

See: Oral delivery of RNase P ribozymes by Salmonella inhibits viral infection in mice. PNAS USA February 7, 2011 doi: 10.1073/pnas.1014975108

PLoS Pathogens: Measles Outbreak in Africa – Is There a Link to the HIV-1 Epidemic?

Friday, February 11th, 2011

To reduce the risk of contracting measles in areas with high HIV-1 prevalence, WHO recommended that infants receive two doses of measles vaccine, at 6 and 9 months. This regimen was evaluated in Zambia and results published in 2008 showed that 59% of children with HIV-1 were measles antibody positive after the first vaccine dose; this number increased to 64% after the second dose. Among HIV-1-exposed non-infected children, 68% and 94% were seropositive after the first and second immunisation, respectively, and similar figures were shown for control children (62% and 92%). To further pinpoint the B cell impairments leading to low antibody levels after measles vaccination in children with HIV-1, Nair characterised early antibody responses to measles following vaccination at 9 months of age. Interestingly, HIV-1 infection impaired IgG responses after vaccination as well as the development of high avidity measles antibodies. In a study from Kenya, antibody titres to measles were evaluated 2 to 5 years after measles immunisation received during the first year of life. Several years after immunisation, only 33% of the children with HIV-1 maintained measles IgG antibodies, indicating impairment in the establishment and the maintenance of serological memory responses.

PLoS Pathogens: Measles Outbreak in Africa—Is There a Link to the HIV-1 Epidemic?